Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

11.90 +0.42 (+3.66%)
Streaming Delayed Price Updated: 12:30 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
 
Via Benzinga
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
OCUL Sales Drop 18%
Via The Motley Fool
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress
OCULAR THERAPEUTIX reported mixed Q2 2025 results, missing revenue and EPS estimates. Stock dipped 6% pre-market but gained 28.5% over the past month. Progress in AXPAXLI™ SOL trials for wet AMD... 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
What's Next: Ocular Therapeutix's Earnings Preview
 
Via Benzinga
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
 
Via Benzinga
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Analyst Expectations For Ocular Therapeutix's Future
 
Via Benzinga
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results. 
Via Benzinga
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
 
Via Benzinga
A Peek at Ocular Therapeutix's Future Earnings
 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock
 
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
 
Via Benzinga
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
 
Via Benzinga
Why Ocular Therapeutix Was Bumping Higher This Week
Via The Motley Fool
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales. 
Via Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026. 
Via Stocktwits
Earnings Scheduled For March 3, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
3 Biotech Stocks to Sell in August Before They Crash & Burn
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.